Vitamin Shoppe (VSI) Receiving Somewhat Favorable Media Coverage, Analysis Shows

Share on StockTwits

Media headlines about Vitamin Shoppe (NYSE:VSI) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vitamin Shoppe earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news stories about the specialty retailer an impact score of 47.0299751533174 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of NYSE VSI traded up $0.90 during midday trading on Friday, hitting $11.85. The company’s stock had a trading volume of 946,708 shares, compared to its average volume of 467,796. Vitamin Shoppe has a 1-year low of $2.95 and a 1-year high of $11.95. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.44 and a current ratio of 1.96. The firm has a market capitalization of $263.38 million, a PE ratio of 30.38 and a beta of 0.57.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings results on Wednesday, August 8th. The specialty retailer reported $0.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.27. Vitamin Shoppe had a negative net margin of 8.76% and a positive return on equity of 2.42%. The business had revenue of $293.10 million during the quarter, compared to analyst estimates of $279.87 million. equities analysts forecast that Vitamin Shoppe will post 0.12 earnings per share for the current year.

Several research analysts have weighed in on the stock. ValuEngine raised shares of Vitamin Shoppe from a “hold” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research raised shares of Vitamin Shoppe from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $3.92.

In other Vitamin Shoppe news, Director Guillermo Marmol purchased 20,000 shares of the firm’s stock in a transaction dated Friday, May 25th. The stock was acquired at an average cost of $5.15 per share, with a total value of $103,000.00. Following the acquisition, the director now owns 29,631 shares of the company’s stock, valued at approximately $152,599.65. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Alex Smith purchased 12,666 shares of the firm’s stock in a transaction dated Tuesday, May 29th. The stock was acquired at an average cost of $5.24 per share, with a total value of $66,369.84. Following the completion of the acquisition, the chairman now directly owns 19,118 shares in the company, valued at approximately $100,178.32. The disclosure for this purchase can be found here. Insiders bought a total of 33,911 shares of company stock valued at $175,906 over the last ninety days. Company insiders own 18.50% of the company’s stock.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

Recommended Story: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply